Know Cancer

or
forgot password

BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy


N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer

Thank you

Trial Information

BRAF, KRAS and EGFR Mutation Detection in Non-Small Cell Lung Cancer Patients Treated With Sorafenib Monotherapy


OBJECTIVES:

- To determine the mutation rates of BRAF, KRAS, and EGFR in patients with non-small cell
lung cancer treated with sorafenib tosylate on protocol ECOG-2501.

- To determine the association between BRAF, KRAS, or EGFR mutation status and clinical
benefits in patients treated with this regimen.

OUTLINE: This is a multicenter study.

DNA is isolated from archived plasma samples and analyzed for BRAF, KRAS, and EGFR
mutations.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of refractory non-small cell lung cancer

- Received sorafenib tosylate on protocol ECOG-E2501

- Available blood specimens

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Mutation rate of sorafenib tosylate-target gene BRAF, and its upstream proteins KRAS and EGFR

Safety Issue:

No

Principal Investigator

Christine Chung, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center

Authority:

Unspecified

Study ID:

CDR0000670998

NCT ID:

NCT01124669

Start Date:

June 2010

Completion Date:

Related Keywords:

  • Lung Cancer
  • recurrent non-small cell lung cancer
  • stage IIIB non-small cell lung cancer
  • stage IV non-small cell lung cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location